Oz Semra, Altindis Mustafa, Toptan Hande, Koroglu Mehmet, Karabay Oguz
Clin Lab. 2020 Jul 1;66(7). doi: 10.7754/Clin.Lab.2019.191122.
Hepatitis E virus (HEV) infection is usually an acute self-limiting disease, which causes rapidly progressive cirrhosis and chronic infection in patients with hematological malignancies, patients requiring chemotherapy, and HIV-infected patients. The aim of this study was to investigate the positivity of hepatitis E IgM and IgG in HIV positive patients with the recently introduced Enzyme Linked Fluorescent Assay (ELFA) commercial kits.
The study included 126 patients who were followed up by the Infectious Diseases and Clinical Microbiology Clinic of Sakarya University Training and Research Hospital between October 2017 and December 2018 for HIV positivity. Serum samples of the patients were evaluated for anti-HEV IgG and IgM positivity with a novel commercially available kit using the ELFA method (bioMerieux, France). The study group consisted of 126 patients with HIV infection. Anti-HEV IgG antibodies were studied primarily from plasma samples. Anti-HEV IgM positivity was also investigated in patients with anti-HEV IgG positivity.
The study group consisted of 114 (90.5%) males and 12 (9.5%) females with a mean age of 38.11 ± 13.32 (min: 18, max: 80) years. Anti-HEV IgG was positive in 5 (4.0%) HIV-positive patients. One of the anti-HEV IgG positive patients was newly diagnosed with HIV and the other four patients were being followed up for HIV positivity. Anti-HEV IgM was negative in all patients. None of the patients with anti-HEV IgG positivity had anti-HCV and HBsAg positivity.
In the study, anti-HEV IgG positivity was found to be 4% in HIV-positive individuals, and no HCV and HBV co-infection was detected in any patients with HIV and HEV coexistence. HEV infections do not emerge as a priority among HIV-infected people, but HEV should also be investigated in HIV-infected individuals with liver abnormalities of uncertain etiology.
戊型肝炎病毒（HEV）感染通常是一种急性自限性疾病，但在血液系统恶性肿瘤患者、需要化疗的患者以及HIV感染患者中可导致快速进展性肝硬化和慢性感染。本研究的目的是使用最近推出的酶联荧光测定法（ELFA）商业试剂盒，调查HIV阳性患者中戊型肝炎IgM和IgG的阳性率。
本研究纳入了2017年10月至2018年12月期间在萨卡里亚大学培训与研究医院传染病与临床微生物学诊所接受HIV阳性随访的126例患者。使用一种新型商业试剂盒，采用ELFA方法（法国生物梅里埃公司）对患者的血清样本进行抗HEV IgG和IgM阳性评估。研究组由126例HIV感染患者组成。主要从血浆样本中研究抗HEV IgG抗体。对抗HEV IgG阳性的患者也进行了抗HEV IgM阳性调查。
研究组包括114例（90.5%）男性和12例（9.5%）女性，平均年龄为38.11±13.32岁（最小：18岁，最大：80岁）。5例（4.0%）HIV阳性患者抗HEV IgG呈阳性。其中1例抗HEV IgG阳性患者为新诊断的HIV患者，另外4例患者因HIV阳性正在接受随访。所有患者抗HEV IgM均为阴性。抗HEV IgG阳性的患者中，无一例抗HCV和HBsAg阳性。
在本研究中，HIV阳性个体中抗HEV IgG阳性率为4%，在任何HIV和HEV共存的患者中均未检测到HCV和HBV合并感染。在HIV感染者中，HEV感染并非首要问题，但对于病因不明的肝脏异常的HIV感染者，也应调查HEV感染情况。
